Department for Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Br J Cancer. 2021 Mar;124(5):857-859. doi: 10.1038/s41416-020-01202-y. Epub 2020 Dec 16.
The therapeutic landscape of drugs targeting the DNA damage response (DDR) is rapidly expanding; however, an urgent unmet need remains for validated predictive biomarkers of response. SLFN11 has emerged as a promising predictor of sensitivity to DNA-damaging chemotherapies, and recently, been associated with sensitivity to PARP inhibition. We discuss its use as a predictive biomarker of response for targeting the DDR.
针对 DNA 损伤反应 (DDR) 的药物治疗领域正在迅速扩大；然而，对于反应的验证性预测生物标志物仍存在迫切的未满足需求。SLFN11 已成为对 DNA 损伤化学疗法敏感性的有希望的预测因子，并且最近与对 PARP 抑制的敏感性相关。我们讨论了将其用作针对 DDR 的反应预测生物标志物的用途。
